Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).

被引：1
|
作者：
Bloudek, Lisa [1 ]
Hepp, Zsolt [1 ]
Mckay, Caroline [1 ]
Derleth, Christina Louise [1 ]
Lill, Jennifer Susan [1 ]
Lenero, Enrique [1 ]
Wright, Phoebe [1 ]
Ramsey, Scott David [1 ]
Sullivan, Sean D. [1 ]
Devine, Beth [1 ]
机构：
[1] Curta Inc, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
570
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) from a United States (US) Medicare and commercial payer perspective
    Ike, Chiemeka
    Kongnakorn, Thitima
    Tichy, Eszter
    Alvarez, Javier Sanchez
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC)
    Gelb, Dave
    Zhong, Yichen
    Perini, Rodolfo Fleury
    Godwin, James Luke
    Lai, Yizhen
    Arndorfer, Stella
    Lorenzi, Maria
    Li, Haojie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [43] BUDGET IMPACT ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS FIRST-LINE (1L) MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED (LA) OR METASTATIC UROTHELIAL CARCINOMA (MUC) IN TAIWAN
    Tsai, Y. C.
    Lin, A. Y.
    Huang, J.
    Wu, E.
    Liu, K.
    Palencia, R.
    Chang, J.
    Kearney, M.
    VALUE IN HEALTH, 2022, 25 (01) : S47 - S47
  • [44] Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.
    Milloy, Neil
    Walley, Maria
    Simpson, Amber
    Forshaw, Cameron
    Morris, Valerie A.
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [45] A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma
    Saxena, Akshat
    Naqvi, Syed Arsalan Ahmed
    Tripathi, Nikita
    Khan, Muhammad Ali
    Bibi, Arifa
    Ballouz, Tara
    Abdul-Muhsin, Haidar
    Tyson, Mark
    Bin Riaz, Irbaz
    Bryce, Alan Haruo
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 639 - 639
  • [46] Pembrolizumab plus axitinib (P plus A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status - a network meta-analysis (NMA)
    McGovern, Ian
    Shirali, Rohan
    Simon, Andrew
    Zhong, Yichen
    Perini, Rodolfo
    Lorenzi, Maria
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [47] First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Wallis, Christopher J. D.
    Klaassen, Zachary
    Bhindi, Bimal
    Ye, Xiang Y.
    Chandrasekar, Thenappan
    Farrell, Ann M.
    Goldberg, Hanan
    Boorjian, Stephen A.
    Leibovich, Bradley
    Kulkarni, Girish S.
    Shah, Prakesh S.
    Bjarnason, Georg A.
    Heng, Daniel Y. C.
    Satkunasivam, Raj
    Finelli, Antonio
    EUROPEAN UROLOGY, 2018, 74 (03) : 309 - 321
  • [48] Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
    Mohammad, N. Haj
    ter Veer, E.
    Ngai, L.
    Mali, R.
    van Oijen, M. G. H.
    van Laarhoven, H. W. M.
    CANCER AND METASTASIS REVIEWS, 2015, 34 (03) : 429 - 441
  • [49] Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
    N. Haj Mohammad
    E. ter Veer
    L. Ngai
    R. Mali
    M. G. H. van Oijen
    H. W. M. van Laarhoven
    Cancer and Metastasis Reviews, 2015, 34 : 429 - 441
  • [50] Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis
    Zhao, Yang
    Xu, Xiaoqing
    Sun, Yuhan
    Yu, Xinyang
    Qi, Yuanfu
    Dai, Xin
    FRONTIERS IN ONCOLOGY, 2024, 14
12345